Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Covista demonstrates stabilization, with Q3 FY2026 revenue up 4.5% and positive enrollment trends across key segments. Chamberlain enrollment reached record levels, but revenue growth remains modest; expansion plans could support future growth, though not aggressively priced in. Management raised FY2026 revenue and adjusted EPS guidance, signaling confidence in earnings power despite margin pressures and regulatory risks.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The mean of analysts' price targets for Covista (CVSA) points to a 27.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Covista (CVSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CVSA surpasses Q3 top and bottom-line estimates as enrollment growth and healthcare demand boosted momentum.
Covista Inc. (CVSA) Q3 2026 Earnings Call Transcript
Covista (CVSA) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $1.92 per share a year ago.
I am bullish on Covista due to sustained enrollment growth driven by technology-enabled and AI-integrated healthcare education. CVSA's partnerships with AI leaders like GE Healthcare's HelloAI and Google Cloud position it to address the widening U.S. physician supply gap. CVSA reported Q2 2026 revenue of $503.4M (12.4% YoY growth), with consistent estimate beats and a P/S multiple below peers despite superior growth.